ESC 365 - Secondary prevention in 2030: will antiplatelets or anticoagulants prevail?

ESC Premium Access

Secondary prevention in 2030: will antiplatelets or anticoagulants prevail?

Session: Antithrombotic therapy for coronary artery disease: opportunities and challenges

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Speaker: Professor D. Angiolillo (Jacksonville, US)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)

26 presentations

2 followers

3 more presentations in this session

State of the Art - New options in antithrombotic therapy for coronary artery disease

Speaker: Professor K. Newby (Durham, US)

Atherothrombotic risk and outcomes following guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome:a post-hoc analysis of the TROPICAL-ACS trial

Speaker: Assistant Professor K. Rizas (Munich, DE)

Frequency, management and outcomes of patients with stable coronary artery disease eligible for COMPASS. An analysis of the CLARIFY registry.

Speaker: Doctor E. Sorbets (Paris, FR)

Access the full session

Antithrombotic therapy for coronary artery disease: opportunities and challenges

Speakers: Professor D. Angiolillo, Professor K. Newby, Assistant Professor K. Rizas, Doctor E. Sorbets

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources